Novo Nordisk's Profit Beat Cannot Settle Investor Doubts

Adjusted profit beat consensus by a wide margin and full-year guidance improved, yet Copenhagen and New York traded the stock in opposite directions as pipeline doubts weighed on sentiment.

Key Takeaways

• Adjusted operating profit rose 11% at constant currency to DKK 33.4 billion, beating the Reuters-polled consensus of DKK 28.7 billion by roughly 16%, a rare scale of upside surprise.
• Full-year guidance improved to 0% to minus 6% at constant currency from minus 12% to minus 4%, following two pipeline failures that erased over $130 billion in market value this year.
• Copenhagen shares closed roughly 2% higher while the New York-listed stock fell about 6% on the same results, a genuine disagreement among investors on two continents.

A Beat That Rewards a Second Look

Novo Nordisk’s second quarter arrived dressed as a triumph and read, on closer inspection, as something more equivocal. The Danish drugmaker’s adjusted operating profit rose eleven percent at constant exchange rates to DKK 33.4 billion, a result that cleared the Reuters-polled consensus of DKK 28.7 billion by a margin few pharmaceutical companies manage to post in a single quarter, let alone one shadowed by a failed cardiovascular trial just days earlier. Net sales climbed a more modest three percent to DKK 78.5 billion, roughly $12.1 billion, and the gap between those two growth rates is itself a clue to how carefully this result deserves to be read.

That gap is not noise. Reported operating profit actually contracted sixteen percent at constant currency, a decline built from two unrelated events colliding in the same set of accounts: a DKK 2.6 billion rebate reversal tied to the American 340B drug pricing program that had inflated the prior year’s comparison, and a DKK 6.3 billion non-cash impairment, four billion kroner of it tied to the abandoned pipeline candidate monlunabant. Strip both away and the underlying business looks considerably healthier than the reported figure suggests, evidence that Novo’s commercial engine, battered as it has been by a year of pipeline disappointments, has not lost its capacity to generate cash.

The Pill Carrying the Franchise

If there is a single figure investors fixate on each quarter, it is the trajectory of oral Wegovy, the pill formulation that has become Novo’s clearest answer to a market growing more crowded by the month. Weekly American prescriptions surpassed 265,000 in the week ending July 17, and cumulative prescriptions since the January launch have crossed five million, a pace of adoption that keeps Wegovy the leading branded obesity treatment by new patient starts even as rivals close in. International rollout has kept step: the pill reached the United Arab Emirates in June and the United Kingdom in July, while the higher-dose Wegovy HD extended its American reach in April.

Yet the quarter carried a small blemish that analysts were quick to seize upon. Oral Wegovy generated DKK 3.22 billion in sales, just short of the DKK 3.27 billion StreetAccount had modeled, a shortfall the company attributed to inventory destocking rather than any erosion in demand. BMO Capital Markets pointed to that miss, together with softer American injectable volumes, as the likely source of the stock’s subsequent weakness. Regulators, at least, offered no such ambiguity: the European Medicines Agency approved both the higher-dose Wegovy pen, on the strength of trial data showing weight loss of up to 20.7 percent, and the pill itself in July, clearing a fuller European rollout for the second half of the year.

When the Pipeline Turns Against You

Novo has spent much of 2026 trying to prove that its future does not depend on a single drug class, and the effort has not gone well. On July 31, days before this earnings release, the company disclosed that ziltivekimab, its experimental anti-inflammatory therapy for cardiovascular disease, failed to reduce major cardiac events in the Phase 3 ZEUS trial, a study that had enrolled more than 6,300 patients with atherosclerotic disease and chronic kidney impairment. The hazard ratio against placebo landed at 0.99, a result indistinguishable from no effect at all, and the market’s response was immediate: Copenhagen shares fell 7.4 percent, the New York-listed shares dropped 8.6 percent, and roughly $30 billion in market value disappeared within a single session.

That failure did not arrive in isolation. In February, CagriSema, the obesity candidate once positioned as Novo’s answer to Eli Lilly’s tirzepatide, failed to demonstrate non-inferiority against its rival in the REDEFINE 4 trial, a result that erased 15.1 percent of the American shares’ value and roughly $100 billion in market capitalization in a single day. A federal judge has since permitted part of a shareholder lawsuit accusing the company of misleading investors about CagriSema’s tolerability to proceed toward discovery. Management’s response has leaned on cost discipline: a restructuring launched in September 2025 eliminated roughly 9,000 positions and targets DKK 8 billion in annualized savings by year end, a program increasingly responsible for protecting margins that the pipeline has repeatedly failed to defend on its own.

Guidance Rises, Confidence Lags

Set against that record, the decision to raise guidance carries real weight. Novo now expects adjusted sales and operating profit to grow between zero and minus six percent at constant currency for the full year, an improvement on the minus twelve to minus four percent range it had previously offered investors. Chief executive Mike Doustdar credited the shift to accelerating American demand and a widening set of international launches, describing the Wegovy franchise as “a key growth driver for Novo Nordisk in 2026.” It is a modest form of optimism, calibrated more toward reassurance than celebration, and the market treated it accordingly.

That optimism also has to survive a pricing reset that Novo itself engineered. Beginning January 1, 2027, the company will cut American list prices for Wegovy, Ozempic, and Rybelsus to $675 a month, reductions of roughly fifty and thirty-five percent respectively, timed to align with new Medicare pricing rules. Eli Lilly, which reports its own results the same week, is not standing still: its oral candidate, marketed as Foundayo, is scaling quickly, and its established injectables continue to erode a market Novo once had almost entirely to itself. Reuters cites analysts who believe the obesity drug category could exceed $100 billion in annual revenue by 2030, a prize now being contested on price as much as on efficacy, and Novo has taken the unusual step of suing Lilly in federal court over what it calls misleading promotional claims, allegations Lilly denies.

Two Tickers, One Verdict Still Open

The clearest evidence of how divided investors remain came not from the earnings call but from the tape itself. Copenhagen-listed shares closed the session up between 1.75 and 2.1 percent, a partial recovery from the ZEUS-driven losses of the previous week. The New York-listed shares told an entirely different story, falling roughly six percent to close near $44.26, as American analysts focused less on the beat and more on the Wegovy pill shortfall and the continued softening of injectable sales at home. Two markets, pricing the same set of numbers, arrived at opposite conclusions within hours of each other.

That split extends into the analyst community itself. Among the 26 analysts covering the Copenhagen shares, the consensus rating remains a hold, and price targets range from DKK 200 to DKK 453, a dispersion wide enough to suggest that no two desks agree on how the contest with Lilly ultimately resolves. A separate panel of 37 American analysts leans more favorably, with roughly 68 percent rating the stock a buy. What both camps appear to share is a sense that the coming quarters, not this one, will determine whether Novo’s pipeline can still produce a genuine second act, or whether Wegovy, for all its scale, is destined to carry the company alone.